These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24072349)

  • 1. Writing PET into existence.
    Chiti A; Kirienko M; Incerti E; Picchio M
    Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):7-10. PubMed ID: 24072349
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.
    Afshar-Oromieh A; Zechmann CM; Malcher A; Eder M; Eisenhut M; Linhart HG; Holland-Letz T; Hadaschik BA; Giesel FL; Debus J; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):11-20. PubMed ID: 24072344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH.
    Afshar-Oromieh A; Haberkorn U; Eder M; Eisenhut M; Zechmann CM
    Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):1085-6. PubMed ID: 22310854
    [No Abstract]   [Full Text] [Related]  

  • 4. [¹⁷⁷Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer.
    Kratochwil C; Giesel FL; Eder M; Afshar-Oromieh A; Benešová M; Mier W; Kopka K; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2015 May; 42(6):987-8. PubMed ID: 25573634
    [No Abstract]   [Full Text] [Related]  

  • 5. PSMA-negative prostate cancer and the continued value of choline-PET/CT.
    Alberts I; Sachpekidis C; Fech V; Rominger A; Afshar-Oromieh A
    Nuklearmedizin; 2020 Feb; 59(1):33-34. PubMed ID: 31766065
    [No Abstract]   [Full Text] [Related]  

  • 6. Intense PSMA-expression using (68)Ga-PSMA PET/CT in a paravertebral schwannoma mimicking prostate cancer metastasis.
    Rischpler C; Maurer T; Schwaiger M; Eiber M
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):193-194. PubMed ID: 26502982
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapy assessment in prostate cancer using choline and PSMA PET/CT.
    Ceci F; Herrmann K; Hadaschik B; Castellucci P; Fanti S
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):78-83. PubMed ID: 28540419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate Cancer Imaging with Novel PET Tracers.
    Lindenberg L; Choyke P; Dahut W
    Curr Urol Rep; 2016 Mar; 17(3):18. PubMed ID: 26874530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging.
    Jadvar H; Calais J; Fanti S; Feng F; Greene KL; Gulley JL; Hofman M; Koontz BF; Lin DW; Morris MJ; Rowe SP; Royce TJ; Salami S; Savir-Baruch B; Srinivas S; Hope TA
    J Nucl Med; 2022 Jan; 63(1):59-68. PubMed ID: 34593595
    [No Abstract]   [Full Text] [Related]  

  • 10. Will GRPR Compete with PSMA as a Target in Prostate Cancer?
    Iagaru A
    J Nucl Med; 2017 Dec; 58(12):1883-1884. PubMed ID: 28970333
    [No Abstract]   [Full Text] [Related]  

  • 11. PSMA as a target for radiolabelled small molecules.
    Eder M; Eisenhut M; Babich J; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):819-23. PubMed ID: 23463331
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecular imaging using PSMA PET/CT versus multiparametric MRI for initial staging of prostate cancer: comparing apples with oranges?
    Mottaghy FM; Heinzel A; Verburg FA
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1397-9. PubMed ID: 27118189
    [No Abstract]   [Full Text] [Related]  

  • 13. First evidence of PSMA expression in differentiated thyroid cancer using [⁶⁸Ga]PSMA-HBED-CC PET/CT.
    Verburg FA; Krohn T; Heinzel A; Mottaghy FM; Behrendt FF
    Eur J Nucl Med Mol Imaging; 2015 Sep; 42(10):1622-3. PubMed ID: 25916744
    [No Abstract]   [Full Text] [Related]  

  • 14. A new perspective for nuclear medicine: expanding the indications for PSMA targeted imaging and therapy.
    Verburg FA; Luster M
    Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1611-1613. PubMed ID: 28677048
    [No Abstract]   [Full Text] [Related]  

  • 15. PSMA PET/CT for staging and treatment of prostate cancer.
    Hofman M
    Clin Adv Hematol Oncol; 2019 Jul; 17(7):370-373. PubMed ID: 31449501
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to Reske et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.
    Afshar-Oromieh A; Malcher A; Eder M; Eisenhut M; Linhart HG; Hadaschik BA; Holland-Letz T; Giesel FL; Kratochwil C; Haufe S; Haberkorn U; Zechmann CM
    Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):971-2. PubMed ID: 23558688
    [No Abstract]   [Full Text] [Related]  

  • 17. PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy.
    Calais J; Czernin J
    J Nucl Med; 2021 Nov; 62(11):1489-1491. PubMed ID: 34725231
    [No Abstract]   [Full Text] [Related]  

  • 18. Comment on Afshar-Oromieh et al.: PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions.
    Reske SN; Winter G; Baur B; Machulla HJ; Kull T
    Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):969-70. PubMed ID: 23558687
    [No Abstract]   [Full Text] [Related]  

  • 19.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-Body Integrated [
    Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
    Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.